Effectiveness of switching from antipsychotic polypharmacy to monotherapy

American Journal of Psychiatry

Volumn 168, Issue 7, 2011, Pages 702-708

  Essock, Susan M ^a,b,c,d,e   Schooler, Nina R ^a,b,c,d,e   Stroup, T Scott ^a,b,c,d,e   McEvoy, Joseph P ^a,b,c,d,e   Rojas, Ingrid ^a,b,c,d,e   Jackson, Carlos ^a,b,c,d,e   Covell, Nancy H ^a,b,c,d,e   Adler, L ^f   Byerly, M ^g   Caroff, S ^h   Csernansky, J ⁱ   D'Souza, C ^j   Jackson, C ^k   Manschreck, T ^l   McEvoy, J ^e   Miller, A ^m   Nasrallah, H ⁿ   Olson, S ^o   Patel, J ^p   Saltz, B ^q   Steinbook, R M ^r   Tapp, A ^s   more..

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Louis Stokes Cleveland Veterans Affairs Medical Center   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f Clinical Insights   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Department of Behavioral Health and Intellectual disAbilities Services   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Yale University School of Medicine   (United States)

^k VETERANS AFFAIRS MEDICAL CENTER   (United States)

^l Laboratory for Clinical and Experimental Psychopathology   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^o UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^p University of Massachusetts   (United States)

^q Mental Health Advocates Inc   (United States)

^r UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^s Veterans Affairs Puget Sound Health Care System   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH; MONOTHERAPY; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; POLYPHARMACY; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79960551424     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2011.10060908     Document Type: Article

References (30)

1. Essock SM, Covell NH, Leckman-Westin E, Lieberman JA, Sederer L, Kealey E, Finnerty MT: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatr Serv 2009; 60:1595-1602
2. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N: Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54:55-59 (Pubitemid 36043847)
3. Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004; 65:1377-1388
4. Centorrino F, Eakin M, Bahk W-M, Kelleher JP, Goren J, Salvatore P, Egli S, Baldessarini RJ: Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 2002; 159:1932-1935
5. Clark RE, Bartels SJ, Mellman TA, Peacock WJ: Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28:75-84 (Pubitemid 34534751)
6. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W; Schizophrenia Patient Outcomes Research Team (PORT): The 2009 Schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71-93
7. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd ed. Am J Psychiatry 2004; 161(Feb suppl)
8. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Rush AJ, Saeed SA, Schooler NR, Shon SP, Stroup S, Tarin-Godoy B: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65:500-508
9. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A: Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997; 171:569-573 (Pubitemid 27527329)
10. Anil Yaǧcioǧlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuǧrul A, Jayathilake K, Göǧüş A, Tunca Z, Meltzer HY: A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: effi cacy and safety. J Clin Psychiatry 2005; 66:63-72
11. Josiassen RC , Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA: Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162:130-136 (Pubitemid 40095682)
12. Honer WG, Thornton AE, Chen EY, Chan RC , Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R; Clozapine and Risperidone Enhancement (CARE) Study Group: Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354:472-482 (Pubitemid 43200298)
13. Freudenreich O, Henderson DC , Walsh JP, Culhane MA, Goff DC: Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92:90-94 (Pubitemid 46561216)
14. Correll CU, Kane JM: Is there a rationale for antipsychotic polypharmacy in schizophrenia? in Schizophrene Störungen: State of the Art III. Edited by Fleischhacker WW, Hummer M. Innsbruck, Austria, Verlag Integrative Psychiatrie, 2004, pp 95-112
15. Suzuki T, Uchida H, Tanaka KF, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H: Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004; 7:133-142 (Pubitemid 38823280)
16. Correll CU, Rummel-Kluge C , Corves C , Kane JM, Leucht S: Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35:443-457
17. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCIDP), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995
18. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276 (Pubitemid 18039085)
19. Schooler NR: Evaluation of drug-related movement disorders in the aged. Psychopharmacol Bull 1988; 24:603-607
20. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
21. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26:25-40 (Pubitemid 30046590)
22. Weiden PJ, Miller A: Which side effects really matter? screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001; 7:41-47
23. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487 (Pubitemid 12152819)
24. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
25. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieber man JA: Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163:2090-2095 (Pubitemid 46114228)
26. Andreasen NC , Pressler M, Nopoulos P, Miller D, Ho BC: Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67:255-262
27. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ: International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167:686-693
28. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: effi cacy and safety of the fi rst long-acting atypical antipsychotic. Am J Psychiatry 2003; 160:1125-1132 (Pubitemid 41070972)
29. Marder SR, Davis JM, Chouinard G: The effects of risperidone on the fi ve dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538-546 (Pubitemid 28100274)
30. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334-1349 (Pubitemid 38989085)